Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    Oxiracetam

    Nootropics

    Status
    Approved (Italy)
    Evidence

    Not graded on a research bench yet

    Oxiracetam is a hydroxylated analog of piracetam, developed in Italy in the early 1980s under the code ISF 2522 and also known as CGP 21690E.

    Reviewed

    01Overview

    What Oxiracetam is

    It was authorized for marketing in Italy under the trade name Neuromet on 21 April 1984 and was studied through the 1980s and 1990s in older patients with degenerative and multi-infarct dementia and with organic brain syndrome. It remains in clinical use in China, where oxiracetam served as the active comparator arm in a multicenter phase 3 trial run from 2019 to 2024 (PMID: 41381424). It has never been approved in the United States. Consumer-facing oxiracetam is sold as bulk powder or capsules under research-chemical terms.

    Read the full overviewShow less

    The molecule carries a chiral center and is normally supplied as the racemate. The S enantiomer, marketed and studied in China as S-oxiracetam or L-oxiracetam, is the active one: in rats with chronic cerebral hypoperfusion, S-oxiracetam and not R-oxiracetam relieved spatial learning and memory impairment, reduced neuron damage and white matter lesions and increased cerebral blood flow (PMID: 28855592). This matters for anyone reading the literature, because racemic and single-enantiomer studies are not interchangeable.

    Mechanistically oxiracetam is less well defined than aniracetam. Rodent work links its behavioral effects to cholinergic function: it antagonized both scopolamine-induced behavioral disruption and the scopolamine-induced fall in hippocampal and cortical acetylcholine in rats, with matching bell-shaped dose-effect curves (PMID: 2602443), and it prevented mecamylamine-induced impairment of active avoidance in mice (PMID: 2356212). It also acts on glutamatergic signaling: it prevented kynurenic acid antagonism of NMDA-evoked noradrenaline release in rat hippocampal slices (PMID: 9336311) and in slices of human neocortex taken during neurosurgery (PMID: 10381808). More recent work in APP/PS1 mice reports that oxiracetam slows desensitization of the GluA1 and GluA2 AMPA receptor subunits (PMID: 41739317).

    Human results are inconsistent across four decades. Positive placebo-controlled results were reported in a 289-patient multicenter trial in degenerative, multi-infarct and mixed dementia (PMID: 2693996) and in several smaller Italian studies. Clearly negative results came from a 24-patient double-blind study in Alzheimer disease, where a broad neuropsychological battery showed no improvement in any patient (PMID: 1444879), and a 106-patient trial in solvent-related organic brain syndrome (PMID: 3296624). The largest modern trial, a 500-patient study commissioned by the South Korean Ministry of Food and Drug Safety, found no difference from placebo on either co-primary endpoint after 36 weeks (PMID: 41614470).

    Regulators have acted on those results. In February 2023 the South Korean drug regulator revoked the vascular cognitive impairment indication and ordered oxiracetam products withdrawn and destroyed after they failed clinical reassessment, and insurance coverage was suspended for seven products. In the United States, the Food and Drug Administration stated in a February 2019 warning letter that oxiracetam is not a dietary ingredient and that products bearing cognitive claims are unapproved new drugs.

    How it works

    Oxiracetam has no single agreed molecular target. Rodent data support a cholinergic component: it reversed scopolamine-induced disruption of passive avoidance and radial maze performance in rats while preventing the associated fall in hippocampal and cortical acetylcholine, with the same bell-shaped dose-effect relationship for both readouts (PMID: 2602443). It also acts on glutamate signaling. In rat hippocampal slices it prevented kynurenate antagonism of NMDA-evoked noradrenaline release in an assay that also responds to glycine-site and GABA-B ligands, which points to an allosteric action on the NMDA receptor complex (PMID: 9336311); the same effect appeared in human neocortical slices (PMID: 10381808). In APP/PS1 transgenic mice, oxiracetam slowed desensitization of the AMPA receptor GluA1 and GluA2 subunits and increased excitatory postsynaptic current frequency and amplitude in hippocampus (PMID: 41739317).

    Studied for

    • Cognitive enhancement
    • Vascular cognitive impairment
    • Traumatic brain injury
    • Nootropics

    Benefits listed

    • Antagonized scopolamine-induced amnesia and the associated fall in hippocampal and cortical acetylcholine in rats (PMID: 2602443)
    • Prevented mecamylamine-induced impairment of active avoidance learning in mice (PMID: 2356212)
    • Facilitated two-way shuttle avoidance acquisition in normal mice (PMID: 3244203)
    • S-oxiracetam, and not R-oxiracetam, relieved spatial learning and memory impairment and reduced white matter lesions in rats with chronic cerebral hypoperfusion (PMID: 28855592)
    Show 2 moreShow less
    • Improved cognitive scores versus placebo over 12 weeks in 289 patients with degenerative, multi-infarct or mixed dementia (PMID: 2693996)
    • Higher Loewenstein cognitive assessment scores than placebo at 90 days for the single enantiomer L-oxiracetam, an advantage not demonstrated for the racemate, in a 590-patient phase 3 trial in mild to moderate traumatic brain injury (PMID: 41381424)

    02Research

    Free with email

    What the research shows

    No research bench grades Oxiracetam yet. Benches compare compounds people pair, with the evidence for each.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    Oxiracetam side effects and interactions

    Side effects

    Not in our record

    Our record lists no side effects for Oxiracetam. That means none are recorded here, not that there are none. The Research section has the written safety notes.

    Who should not use it

    Contraindications

    Renal impairment is the main pharmacokinetic caution: oxiracetam is excreted essentially unchanged by the kidney and its terminal half-life rose from about 8 hours to as much as 68 hours as creatinine clearance fell (PMID: 2253654; PMID: 6519128). A pilot study found that concurrent carbamazepine or valproic acid shortened the oxiracetam half-life, although oxiracetam did not alter antiepileptic drug serum concentrations (PMID: 2108837). No human pregnancy or lactation safety data have been published; in pregnant rats, radiolabeled oxiracetam crossed the placenta into fetal tissue reversibly and to a limited extent (PMID: 1499599).

    Interactions

    Not in our record

    Our record lists no interactions for Oxiracetam. That means none are recorded here, not that none exist.

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    Dosing

    No dose on record

    Our record lists no dose for Oxiracetam. This section holds what it does list.

    Unlock the Dosing section

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • Route

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    Oxiracetam prices

    1 listing from 1 vendor, opening in the Featured order.

    Pack prices
    $74.99
    Lowest per mg
    $2.50/g
    Vendors
    1
    Listings
    1 (capsule)

    Prices as the vendors list them, last recorded 7 September 2026.

    Form
    Sort
    Oxiracetam listings, in Featured order
    VendorProductPriceBuy

    Oxiracetam 500 mg capsules (60)

    capsule, 60 capsules (500 mg)

    In stock

    $2.50/g

    $74.99

    Lowest per mg
    Buy Oxiracetam 500 mg capsules (60) at Disguised Alpha
    Vendors selling Oxiracetam(1: trust score, certificates, payment, shipping)

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Review Oxiracetam

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Oxiracetam.

    06Chemistry

    Chemistry and structure

    Molecular formula
    C6H10N2O3
    Molecular mass
    158.16 g/mol
    CAS number
    62613-82-5
    Half-life
    About 8 hours in healthy adults. Mean terminal half-life was 7.7 hours in healthy non-geriatric subjects and 12.3 hours in elderly patients after oral dosing (PMID: 2253653), and 10.6 to 68.1 hours in patients with renal impairment, correlating with creatinine clearance (PMID: 2253654). More than 90 percent of an intravenous dose is recovered unchanged in urine within 48 hours, and absolute oral bioavailability was 75 percent in healthy volunteers (PMID: 6519128).
    View on PubChem

    08Questions

    Frequently asked questions

    What is Oxiracetam used for in research?

    Oxiracetam is a hydroxylated analog of piracetam, developed in Italy in the early 1980s under the code ISF 2522 and also known as CGP 21690E. It was authorized for marketing in Italy under the trade name Neuromet on 21 April 1984 and was studied through the 1980s and 1990s in older patients with degenerative and multi-infarct dementia and with organic brain syndrome. It remains in clinical use in China, where oxiracetam served as the active comparator arm in a multicenter phase 3 trial run from 2019 to 2024 (PMID: 41381424). It has never been approved in the United States. Consumer-facing oxiracetam is sold as bulk powder or capsules under research-chemical terms.

    The molecule carries a chiral center and is normally supplied as the racemate. The S enantiomer, marketed and studied in China as S-oxiracetam or L-oxiracetam, is the active one: in rats with chronic cerebral hypoperfusion, S-oxiracetam and not R-oxiracetam relieved spatial learning and memory impairment, reduced neuron damage and white matter lesions and increased cerebral blood flow (PMID: 28855592). This matters for anyone reading the literature, because racemic and single-enantiomer studies are not interchangeable.

    Mechanistically oxiracetam is less well defined than aniracetam. Rodent work links its behavioral effects to cholinergic function: it antagonized both scopolamine-induced behavioral disruption and the scopolamine-induced fall in hippocampal and cortical acetylcholine in rats, with matching bell-shaped dose-effect curves (PMID: 2602443), and it prevented mecamylamine-induced impairment of active avoidance in mice (PMID: 2356212). It also acts on glutamatergic signaling: it prevented kynurenic acid antagonism of NMDA-evoked noradrenaline release in rat hippocampal slices (PMID: 9336311) and in slices of human neocortex taken during neurosurgery (PMID: 10381808). More recent work in APP/PS1 mice reports that oxiracetam slows desensitization of the GluA1 and GluA2 AMPA receptor subunits (PMID: 41739317).

    Human results are inconsistent across four decades. Positive placebo-controlled results were reported in a 289-patient multicenter trial in degenerative, multi-infarct and mixed dementia (PMID: 2693996) and in several smaller Italian studies. Clearly negative results came from a 24-patient double-blind study in Alzheimer disease, where a broad neuropsychological battery showed no improvement in any patient (PMID: 1444879), and a 106-patient trial in solvent-related organic brain syndrome (PMID: 3296624). The largest modern trial, a 500-patient study commissioned by the South Korean Ministry of Food and Drug Safety, found no difference from placebo on either co-primary endpoint after 36 weeks (PMID: 41614470).

    Regulators have acted on those results. In February 2023 the South Korean drug regulator revoked the vascular cognitive impairment indication and ordered oxiracetam products withdrawn and destroyed after they failed clinical reassessment, and insurance coverage was suspended for seven products. In the United States, the Food and Drug Administration stated in a February 2019 warning letter that oxiracetam is not a dietary ingredient and that products bearing cognitive claims are unapproved new drugs.

    What forms does Oxiracetam come in?

    Oxiracetam is available in capsule form.

    How do I compare Oxiracetam vendors?

    Compare prices, payment methods, shipping, and COA scores across 1 vendor.

    How many vendors sell Oxiracetam, and what does it cost per mg?

    1 of the vendors BodyHackGuide tracks list Oxiracetam (1 listing). Among BodyHackGuide's Oxiracetam listings recorded as in stock with a milligram count, the lowest price per milligram is $2.50/g at Disguised Alpha and the median is $2.50/g. The Oxiracetam prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Oxiracetam listing is dated 7 September 2026.

    Which vendors have third-party COAs for Oxiracetam on file at BodyHackGuide?

    BodyHackGuide holds no third-party certificate records for Oxiracetam. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor.

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free